{"ticker": {"uuid": "41a59536-c8b5-4d85-a0e6-acfdd4b6ccea", "symbol": "LNTH", "name": "Lantheus Holdings Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Drug Manufacturers - Specialty & Generic"}, "articles": [{"title": "Lantheus Holdings (LNTH) Could Be 2% Undervalued Following Its Alzheimer Imaging Narrative", "summary": "Lantheus Holdings (LNTH) is gaining attention due to strong stock performance and its Alzheimer's disease imaging franchise, despite concerns about slowing revenue and margin pressures. The company's radiodiagnostic pipeline, including an FDA label expansion for Neuraceq and the ", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-lnth/lantheus-holdings/news/lantheus-holdings-lnth-could-be-2-undervalued-following-its/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-15T08:12:38", "published_display": "15 Jul 2026 08:12", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantheus Holdings, Inc. (LNTH) Stock Analysis: A 4.44% Potential Upside in the Healthcare Sector", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxQcVB2THhLQ0hmeDdsTmJYM1ZpR3I0YjF4UEJVMkhDWHkxZlVzVllBX2JtZlpGdEJNQ09kZEF0c3d1TWdyOXZadGN5VTl1R2RsWFpWQW44cVhkdGd4amtSRWJhQWwxMVMwT1g2NEhHYnZJQ2dQWG1sSlJSbDVxdjlKNENUV3ZOZW01N0QwQklEYm5FUjFzTGxjU3dkcUQzTGVodzRiclNpT3dGenZnaEJuSUphRGZfV3JTeG1yekkzSTFnZVRqV1hqR3o1NmVQd1dtVVhyQ29BWU0?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-13T09:22:36+00:00", "published_display": "13 Jul 2026 09:22", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantheus (LNTH) Q4 2024 earnings summary", "summary": "Lantheus (LNTH) reported record FY2024 revenue of $1.534 billion, an 18.3% year-over-year increase, primarily driven by strong sales of PYLARIFY and DEFINITY. PYLARIFY achieved blockbuster status with over $1 billion in annual sales, and DEFINITY also showed double-digit growth. ", "url": "https://quartr.com/events/lantheus-holdings-inc-lnth-q4-2024_oqQB0p8C", "source_name": "Quartr", "published_at": "2026-07-11T06:10:30", "published_display": "11 Jul 2026 06:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantheus (LNTH) M&A Announcement Summary", "summary": "Lantheus (LNTH) has announced an M&A deal designed to transform it into a fully integrated radiopharmaceutical leader by expanding manufacturing, broadening its pipeline, and entering new markets. The deal includes an upfront cash payment of $250 million plus up to $752.5 million", "url": "https://quartr.com/events/lantheus-holdings-inc-lnth-m-a-announcement_oqQB0xFg", "source_name": "Quartr", "published_at": "2026-07-11T02:41:14", "published_display": "11 Jul 2026 02:41", "sentiment": "positive", "sentiment_pct": 74, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantheus (LNTH) Q3 2025 earnings summary", "summary": "Lantheus reported Q3 2025 revenue of $384 million, a modest 1.4% year-over-year increase, with adjusted EPS at $1.27 and GAAP EPS significantly lower due to a 78.8% drop in net income. The company announced a leadership transition, completed key acquisitions of Life Molecular Ima", "url": "https://quartr.com/events/lantheus-holdings-inc-lnth-q3-2025_oqQB0zHN", "source_name": "Quartr", "published_at": "2026-07-11T02:41:14", "published_display": "11 Jul 2026 02:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "B. Riley Adjusts Price Target on Lantheus Holdings to $129 From $97, Maintains Buy Rating", "summary": "B. Riley has increased its price target for Lantheus Holdings (LNTH) to $129 from $97, while reiterating a Buy rating on the stock. This adjustment reflects a positive outlook on the company's financial prospects and market position.", "url": "https://www.moomoo.com/news/post/72719595/b-riley-adjusts-price-target-on-lantheus-holdings-to-129", "source_name": "Moomoo", "published_at": "2026-07-09T15:13:06", "published_display": "09 Jul 2026 15:13", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(LNTH) Movement as an Input in Quant Signal Sets", "summary": "This article provides a quantitative analysis of Lantheus Holdings Inc. (NASDAQ: LNTH), highlighting a weak near-term sentiment that could precede shifts in mid and long-term outlook. It identifies an exceptional 42.1:1 risk-reward short setup targeting a 12.0% downside against 0", "url": "https://news.stocktradersdaily.com/news_release/89/LNTH_Movement_as_an_Input_in_Quant_Signal_Sets_070826032201_1783538521.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-08T15:22:00", "published_display": "08 Jul 2026 15:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantheus Holdings Inc focuses on diagnostic imaging growth", "summary": "Lantheus Holdings Inc (LANT) specializes in advanced diagnostic imaging agents and therapeutic solutions, primarily for cardiovascular and oncology applications in the US market. The company's strategy focuses on innovation, rigorous clinical evidence, and navigating complex regu", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/lantheus-holdings-inc-focuses-on-diagnostic-imaging-growth/69716972", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T19:10:24", "published_display": "07 Jul 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantheus Holdings Inc (LNTH) Stock Down 6.4% but Still Overvalued -- GF Score: 82/100", "summary": "Lantheus Holdings Inc (LNTH) shares dropped 6.4% to $102.82 but are still considered overvalued according to GuruFocus's GF Value\u2122 which estimates its intrinsic value at $90.77. Despite a strong GF Score\u2122 of 82/100, indicating robust fundamentals in profitability and growth, its ", "url": "https://www.gurufocus.com/news/8946324/lantheus-holdings-inc-lnth-stock-down-64-but-still-overvalued-gf-score-82100", "source_name": "GuruFocus", "published_at": "2026-07-06T23:40:30", "published_display": "06 Jul 2026 23:40", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Did FDA\u2019s Facility-Related LNTH-2501 Delay and Russell Additions Just Reframe Lantheus Holdings\u2019 (LNTH) Risk Profile?", "summary": "Lantheus Holdings received a Complete Response Letter from the FDA for its LNTH-2501 PET imaging kit due to third-party manufacturing facility issues, not product safety or efficacy. Concurrently, the company was added to the Russell 2000 Defensive and Growth-Defensive Indexes, i", "url": "https://www.sahmcapital.com/news/content/did-fdas-facility-related-lnth-2501-delay-and-russell-additions-just-reframe-lantheus-holdings-lnth-risk-profile-2026-07-03", "source_name": "Sahm", "published_at": "2026-07-05T04:10:33", "published_display": "05 Jul 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LNTH - Lantheus Holdings Inc Latest SEC Filings", "summary": "This article provides the latest SEC filings information for Lantheus Holdings Inc. (LNTH), along with comprehensive financial data, performance metrics, and key ratios. It includes details on the company's market capitalization, income, sales, P/E ratio, insider ownership, insti", "url": "https://finviz.com/stock?t=LNTH&ta=1&p=d&ty=lf&b=2&page=20", "source_name": "Finviz", "published_at": "2026-07-04T16:39:52", "published_display": "04 Jul 2026 16:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantheus Holdings Inc focuses on diagnostic imaging and radiopharmaceutical growth", "summary": "Lantheus Holdings Inc is a specialized medical technology company that develops diagnostic imaging agents and radiopharmaceuticals for cardiology and oncology. The company's products help physicians visualize disease processes and improve diagnostic accuracy. Lantheus aims for lo", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/lantheus-holdings-inc-focuses-on-diagnostic-imaging-and/69680972", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-03T15:04:28", "published_display": "03 Jul 2026 15:04", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantheus Holdings stock hits 52-week high at 111.52 USD", "summary": "Lantheus Holdings stock reached a new 52-week high of $111.52, reflecting a strong 39.74% increase over the past year and investor confidence. This comes despite a recent FDA regulatory setback for its LNTH-2501 imaging kit due to manufacturing issues. Analysts like Citizens and ", "url": "https://www.investing.com/news/company-news/lantheus-holdings-stock-hits-52week-high-at-11152-usd-93CH-4768293", "source_name": "Investing.com", "published_at": "2026-06-30T16:10:08", "published_display": "30 Jun 2026 16:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantheus Holdings, Inc. (LNTH) Stock Analysis: Strong Buy Ratings Amid Impressive ROE and Expanding Diagnostic Portfolio", "summary": "Lantheus Holdings, Inc. (LNTH) is a strong player in the healthcare sector, particularly in diagnostic and therapeutic products, indicated by its $7.15 billion market cap and robust stock performance. The company exhibits impressive financial health with a 23.48% Return on Equity", "url": "https://www.directorstalkinterviews.com/lantheus-holdings-inc-lnth-stock-analysis-strong-buy-ratings-amid-impressive-roe-and-expanding-diagnostic-portfolio/4121255029", "source_name": "DirectorsTalk Interviews", "published_at": "2026-06-29T14:09:36", "published_display": "29 Jun 2026 14:09", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantheus Holdings (LNTH) New Product Narrative Keeps Valuation Questions In Focus", "summary": "Lantheus Holdings (LNTH) shares have recently seen significant movement, prompting investors to re-evaluate the company's valuation in light of its diagnostics and radiopharmaceutical portfolio. While market ratios suggest a balanced valuation, the company is considered modestly ", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-lnth/lantheus-holdings/news/lantheus-holdings-lnth-new-product-narrative-keeps-valuation", "source_name": "Simply Wall Street", "published_at": "2026-06-28T22:43:03", "published_display": "28 Jun 2026 22:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA issues complete response letter for Lantheus\u2019 NET imaging drug", "summary": "The FDA has issued a Complete Response Letter for Lantheus Holdings Inc.'s NET imaging drug, LNTH-2501, due to unresolved manufacturing issues at a third-party facility. The FDA's decision is not related to the drug's safety or efficacy data. Despite this setback, Lantheus shares", "url": "https://www.investing.com/news/company-news/fda-issues-complete-response-letter-for-lantheus-net-imaging-drug-93CH-4763391", "source_name": "Investing.com", "published_at": "2026-06-27T13:10:15", "published_display": "27 Jun 2026 13:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Lantheus Holdings, Inc. \u2013 NASDAQ:LNTH", "summary": "This page displays the enterprise value to revenue forward for Lantheus Holdings, Inc. (NASDAQ: LNTH). It provides financial data and historical values for this specific metric. The content appears to be a financial data point from TradingView related to the company's valuation.", "url": "https://www.tradingview.com/symbols/NASDAQ-LNTH/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T03:09:44", "published_display": "27 Jun 2026 03:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantheus stock falls after FDA rejects drug application By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxPRjlJSEE2RHZTQmlLZWgyUjdHQUMyNThkYzZ2U09Sbnd5WW9MRkVXQTVzbEROMDFleFdRN3R6TkdGMHA0Vm80bDBJTUtOYjFCd0ZlTnladVNlYlp6X1dibkdqMERiR29CY0FkaGRZX05EZnU2QWhhN3VHRlFyaG1FQjlPQUY3dHVQNGxfcHJyWDZyR1J4eV9fcmUxeXo2U2dMY0FidjE0THo2NGZNMmRkRkQ5X2pBZ1k?oc=5", "source_name": "Investing.com South Africa", "published_at": "2026-06-26T22:44:03+00:00", "published_display": "26 Jun 2026 22:44", "sentiment": "negative", "sentiment_pct": 22, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantheus Gets FDA Complete Response Letter for LNTH-2501", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/lantheus-gets-fda-complete-response-202202784.html", "source_name": "MT Newswires", "published_at": "2026-06-26T20:22:02+00:00", "published_display": "26 Jun 2026 20:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Lantheus Holdings, Inc. \u2013 NASDAQ:LNTH", "summary": "This page displays the forward Price to Sales ratio for Lantheus Holdings, Inc. (NASDAQ:LNTH). It appears to be a financial data point from TradingView, indicating a specific valuation metric for the company.", "url": "https://www.tradingview.com/symbols/NASDAQ-LNTH/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T21:10:58", "published_display": "26 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantheus stock falls after FDA rejects drug application", "summary": "Lantheus Holdings Inc. shares dropped after the FDA issued a Complete Response Letter for its LNTH-2501 drug application, citing unresolved manufacturing issues at a third-party facility. The FDA's decision was not related to the clinical safety or efficacy data of the drug, whic", "url": "https://www.investing.com/news/stock-market-news/lantheus-stock-falls-after-fda-rejects-drug-application-93CH-4763670", "source_name": "Investing.com", "published_at": "2026-06-26T21:10:58", "published_display": "26 Jun 2026 21:10", "sentiment": "negative", "sentiment_pct": 19, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US FDA declines Lantheus\u2019 tumor imaging kit over third-party manufacturing issues", "summary": "The U.S. FDA has declined to approve Lantheus Holdings' diagnostic imaging kit, LNTH-2501, for cancer tumors due to unresolved issues at a third-party manufacturing facility. This marks a setback for Lantheus, although the company stated that the FDA raised no concerns about the ", "url": "https://www.reuters.com/legal/litigation/us-fda-declines-approve-lantheus-tumor-imaging-kit-2026-06-26/", "source_name": "Reuters", "published_at": "2026-06-26T20:12:00", "published_display": "26 Jun 2026 20:12", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantheus Receives Complete Response Letter from FDA for LNTH-2501 (Ga 68 edotreotide)", "summary": "Lantheus announced that the FDA issued a Complete Response Letter for its New Drug Application for LNTH-2501, a diagnostic imaging agent for neuroendocrine tumors. The FDA's decision was due to unresolved manufacturing conditions at a third-party facility, not concerns about the ", "url": "https://www.manilatimes.net/2026/06/27/tmt-newswire/globenewswire/lantheus-receives-complete-response-letter-from-fda-for-lnth-2501-ga-68-edotreotide/2373966/amp", "source_name": "The Manila Times", "published_at": "2026-06-26T20:10:58", "published_display": "26 Jun 2026 20:10", "sentiment": "negative", "sentiment_pct": 10, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Lantheus Holdings Inc \u2013 XETR:0L8", "summary": "This article focuses on the \"Price to book forward\" metric for Lantheus Holdings Inc (XETR:0L8) as presented on TradingView. It appears to be a financial data snippet or a specific page from a financial tracking platform, indicating that the market for this stock is currently clo", "url": "https://www.tradingview.com/symbols/XETR-0L8/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T19:10:58", "published_display": "26 Jun 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantheus Holdings Inc Actuals & Estimates (NASDAQ:LNTH)", "summary": "This article provides an overview of Lantheus Holdings, Inc. (NASDAQ:LNTH) stock, including its current price, market capitalization, and historical performance. It also details analyst forecasts, financial actuals and estimates for earnings and revenue, and key financial metrics", "url": "https://www.tradingview.com/symbols/NASDAQ-LNTH/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T01:09:35", "published_display": "26 Jun 2026 01:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LNTH Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a detailed analyst forecast for Lantheus Holdings, Inc. (LNTH) stock for 2027, including a price target of 107.82 USD, with a max estimate of 117.00 USD and a min estimate of 94.00 USD. It covers various financial metrics such as price performance, market ca", "url": "https://www.tradingview.com/symbols/NASDAQ-LNTH/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T14:10:10", "published_display": "25 Jun 2026 14:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Beat And Cautious Outlook Could Be A Game Changer For Lantheus Holdings (LNTH)", "summary": "Lantheus Holdings (LNTH) recently surpassed Q1 analyst expectations for revenue and EPS due to strong demand for key products, while also reiterating its long-term plan. However, the company's full-year revenue guidance unexpectedly fell below analyst forecasts, indicating a caut", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-lnth/lantheus-holdings/news/earnings-beat-and-cautious-outlook-could-be-a-game-changer-f", "source_name": "Simply Wall Street", "published_at": "2026-06-25T04:40:23", "published_display": "25 Jun 2026 04:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Healthcare Equipment and Supplies Stocks Q1 Teardown: Lantheus (NASDAQ:LNTH) Vs The Rest", "summary": "This article analyzes the Q1 2026 earnings for healthcare equipment and supplies stocks, highlighting top performers like Lantheus (NASDAQ:LNTH) and STAAR Surgical (NASDAQ:STAA), and weaker performers such as Stryker (NYSE:SYK). It discusses industry trends, including innovation,", "url": "https://stockstory.org/us/stocks/nasdaq/lnth/news/earnings/healthcare-equipment-and-supplies-stocks-q1-teardown-lantheus-nasdaqlnth-vs-the-rest", "source_name": "StockStory", "published_at": "2026-06-24T09:10:24", "published_display": "24 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantheus Holdings stock hits 52-week high at 107.99 USD By Investing.com", "summary": "Lantheus Holdings Inc. (LNTH) stock reached a 52-week high of $107.99, demonstrating strong market performance with a significant year-to-date return of 59.58%. This achievement coincides with the company reporting strong Q1 2026 financial results, surpassing analyst expectations", "url": "https://ca.investing.com/news/stock-market-news/lantheus-holdings-stock-hits-52week-high-at-10799-usd-93CH-4703639", "source_name": "Investing.com", "published_at": "2026-06-23T15:09:25", "published_display": "23 Jun 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantheus: The Turnaround Is Working, But The Easy Money Has Been Made (NASDAQ:LNTH)", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxNQmdMZzB5WHh5UUo3aG9Zem54VEtid2tuV2RiWElya24tU3lXTXA5NGljVy10V0VFbHRoQklJTHlfa3VTMkxlRHhXUW1CSE05ajJoRGg3SzNoY3Y5R0hxQVhLMGZYSG0zM1Z2aTF3ZWE2dFIydWJnTlB1N0phcVBsMnRkcWVqZDM5RmJiNGxjZk54dUgwWXcwMDRCQmRfMi1XREJxZkN2MDNiRkwyR3hR?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-20T07:00:00+00:00", "published_display": "20 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantheus Holdings Inc (LNTH) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article provides an overview of the shareholder structure of Lantheus Holdings Inc (LNTH), detailing its major shareholders and institutional holdings. It lists the top institutional investors, including BlackRock, Janus Henderson Investors, and Farallon Capital Management, ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lnth/ownership", "source_name": "TradingKey", "published_at": "2026-06-19T18:10:29", "published_display": "19 Jun 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantheus (LNTH) Proxy filing Summary", "summary": "Lantheus (LNTH) recently filed a proxy statement detailing its upcoming annual meeting on April 30, 2026. Key items for shareholder vote include the election of four Class II directors, advisory votes on executive compensation, and a proposal to declassify the Board of Directors.", "url": "https://quartr.com/events/lantheus-lnth-proxy-filing_oqQBzjsc", "source_name": "Quartr", "published_at": "2026-06-19T14:10:29", "published_display": "19 Jun 2026 14:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantheus Holdings stock hits 52-week high at 104.05 USD", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxOTklNSXBHMkRPZXd5QnM3ZWh6cWdLMF83Q1JKeGVpa210NG1XYnFyUHptc2phWEtnY3J0WnRacUlGczg4T0ZRNGRsZFBzVS1jOVEzcFJxN29qVjNfeG4wenBUZy0yT1p1aUhTS3RNVkl0YkUzWmUxQ2RGRG9haExleEZuUVpwR0NrTUhvdjJQTWJKVkZXTUU2bUJKZ053Nm9nVUlvYWFkX01NLXhjbllR?oc=5", "source_name": "Investing.com", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Lantheus Holdings (LNTH) Valuation After Strong Multi Month Share Price Gains", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxOYkNrMm5kVFA5T2w0MkRzWlNTeW1SZzBleDE5RzJUQ0ZET2xmbERLVHk2MUk0OV9qMFpIeHJMb29zNGQzOEx5M0thUHFEaUx5V2pveGZKU2dCdXZiUHdlVFczT2xzVHk2dG9LVkdHTGpZaUVLRHVGbzhlQV9ZRFEtaVlyYkRfUE1JYThwczhHTkdQOHQ4V3NUUkZTQm9Nck81TTFnaU5EOHlXZWM?oc=5", "source_name": "Market source", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantheus (LNTH) CEO Heino reports 1,227-share tax withholding and updated holdings", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxOQlZObGdhdVU5VDlKYlpyY2JoQ1dfclRBNFZMVlgwdzhuUkJCUnhtVGJXbl9vYklmUTV5dXVSVXJRbHhBbkM3eTNHMXJweXo0c0ZqdVo1RVVDTi1BOTE5dkFFeU9TOEgwbGNMbmc0VWIwOUMxT3ZFMEE0blZCUnJnSnVpSEFBOTA2cXNzX3lndEJHNncxVFhJbEFaTlYycC1COW9iNFFmbkNkaDV6WnhMUzNOVVFXZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Radiopharma firm Lantheus to speak at Goldman Sachs health event", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxPM1FPNU1vVWp2OG5LQTE1OV9ybDMtVnpoTjVvQWpZUlMySlpmaWtHblNZeGlaMXRWUWYyc2NjVDdFVjBrTTJNa1oxWk5oQ25YeHZTOUo0MHNXS29YcEM2aHIzQjh5N2JBeTdiZ3FNT0t3b3RNMFdmcmthWnJBTWFBMzJMcmlaclg1dHBjWUwtZm5XemNENUR2a2Z6QmdmUEI0WDAtaHgyaUh6djlzUUVjRDBHTTc?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantheus ASCO Data To Test Radiopharma Pipeline And Valuation Gap Narrative", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Too Late To Consider Lantheus Holdings (LNTH) After Its Strong Share Price Run?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxNbXdlZlo2S0o4MVFfTFJMX3BjLTg5Y3NoczJ2bjRFOWRzSWpQUUdOSURKTnhDMkFFRkxlRURaV3FSSHpPX1VTdEVQUWtXeE1MMkp2MzQ3LVNtdlBoTGZWNWpPLVgyNzk0aU8wODdaR283UVl3b2tsQ0NZdVJZR2ZUQ3ZKNlRVckRHSTB6WUN6QUFjcU5Yd2lTcXVXaUcza0sxcWdDNGFvTHI4NmUweHBDckxXRTI3QVl4Q2RaNUwwQkJqajhLVUtid0VXZXZPZVo4eG5r0gHYAUFVX3lxTFBTR3lSdENzcHhQVkNWcjVqeXFKWDB0aEx4Q3BwWjJzeFJEVlh3M1BwY2VHQXlaM3h4dmsycUhLWmNnM0o3dDZvSGQ2cW9QaW9uT1g0aTJBbjhTdk4yanhZRzdEUlM2OEtMOFVVVU5rdGVjM1Z6VVVyZVVER1ZuUml3dnY2LUZHdDBOWUp1aU5DNk8yOXAwVWsxOEJ3ZUljbm5qS0JaQjVwNkc1R05RVEZZTUZDbmhaMGpqemhlTFNKSTBTVUgzckdPa0VjdTB0WE45OGRrbExzcg?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-24T07:00:00+00:00", "published_display": "24 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Story On Lantheus Holdings (LNTH) Is Shifting With PYLARIFY And Pipeline Expectations", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNckNrY1NXSHFyR3RQVWpWTEFDOTY1M1hfSFhoSkNzaGc1b055Z0k0c3poM29NaFpmaEJmYk9UcFBHS0IxRzFtM2RIb1ZzVFJLVkgzb1lsS3pOMXhUbDliN2VGaFVwcTl2ekd4N2lYc0V1bGhNQmJRcmpsLVZDZmdfX1FtT2wwNlhzYTNSYnpEckZzTVBPWm84MHlrVGJzT2VrQzk2ZA?oc=5", "source_name": "Market source", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantheus (LNTH) Considers Sale Following Curium Acquisition Prop", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxQbmQ5c0M0NnJDbElOem9YYy00Ym8xekItY3BINVFaSlA3dk1FOEhlZVhlcW85R0UyYS04WWFjeU4zOWt0VHB1MkdHQTZJUU5zV3I5Z3MtS294UVY1Yi1xRlhuVTJUVUtNRjhtTmtiREFWWW5GNXlTY1NGRGJnYzAzUWZhcS0ybElSN1dGTmJmeWlvLWEzZXVGTW9jbG5VdTBVRWVYbF9XWW1CSWF3SmpHT3kyV0xrcEFuZzBHV3V1VXd4ZmNFcERsYm14R0Ffdw?oc=5", "source_name": "GuruFocus", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantheus weighs potential $7 billion sale after Curium's offer, Bloomberg News reports", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQNkRQbmVpZUotZHFVdFNYaWpaOHZ6SkpId0xSSHd2NWtyNy1wZHJSa05pZ09OTlp1TGtZOHJReTdFUU9SOTBpeDN2dm51QVFFNVVYRlRaWHQtTnhSZVg4NzFyb0N2dk9mZXMzSUlDQy1STlJHd1JYMUwwNHprUjB5MlgwT0o0ZURzTEdua1dOQnA5cGQwUktsUXZQcExvSFhFWnJDaElKOTd5ZlNodFI1V1JGRWNUSVh0WXhF?oc=5", "source_name": "Reuters", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We Think You Should Be Aware Of Some Concerning Factors In Lantheus Holdings' (NASDAQ:LNTH) Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantheus Holdings (LNTH) Valuation Check After Q1 Earnings Beat And FDA Approval Catalysts", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxPUUtEaVdZdHhkSE8tZUc3VEZzN010MTVMeDI2eFRISS1NRmhaUmF2NjdRV2hKaWN4a1pyM0RhbGNWeUd6TFhEYXJlendTNXNWMGJNS09taVJXYlExa3NYR3A3Qk5pZ0pGWW93WUFVbXB2NEI2X3A3TWlyYlF1UXVjdEJjc1RXQzQzSWdtdVlJamRqWmtCRVlKallvVV91QWM0OUo3aGtR?oc=5", "source_name": "Market source", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here is Why Lantheus Holdings Inc (LNTH) Is Among the Best Medical AI Stocks to Invest In", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOZ3JuY2thSGRvQjJIclFnVVAySTRJNlBQV3NTT2ZtdFJjSm5RbEs1Wjh5Qk5kWnoyRjhlc0ltUDVKVGc2aEhVWDZxR2NoTUxrVUdEOVpJenRoaHdzeUpRNm9IZTZvdjA3UkZqbzdXaGpCbHBYMzBqdmxoakd4WU54X0Z5R3BlRjNmblVjdlAtMmNxaW1OQnNNOVpkRV91czBB?oc=5", "source_name": "Market source", "published_at": "2026-04-19T07:00:00+00:00", "published_display": "19 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantheus Says FDA Pushed Deadline For Reviewing Its Tumor Diagnostic Kit Application", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxNNkVRWHFkNDVuSno0ZDJVMzhpNF9oTm1WS2hBLVZ6ZkJBbDhZVEUyRm90NzdZbGVqeVV4aDJ3aWZEeWFFRDhJeTdMX3E3MjJJZVVnTG5KeUNmV2NLM3dlREd2YmpnWDI5TGpaS0gxOElYa1RzSEtBWVRBQnpyOW5VX2RTMERrZUtMQkFyMzVaX1JlMUZqSUtxZmx3bFNxa3lLR3lqcnVGU2tEbzgyaHdQaS1hSlFBTFB0LUVlSXJaNFlnY3pCeE5rckl2dE5admFSeGMwLW5qUjk1LWdm?oc=5", "source_name": "Stocktwits", "published_at": "2026-03-17T07:00:00+00:00", "published_display": "17 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA extends review of Lantheus\u2019 neuroendocrine tumor drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxNTzlnNG1WT0U3QlRrLXRZYmNpRTNXTW83TjB5Ml8xOThuSDhjam1kbUNiYWhkNG43RkNXRGNCc3V0ZWFib0dfSXE1UnhTVkZIWDVUT1FqWUtJdWJhSjRFT3h4RGh6UEczajdFZmJJV1E3MFJDbzZmczQtS1pCSHR5TnItbUpIVnBfbkN3cmNYdnBFNEpvUl84Nkpmei00bTd3TFVubllRNnVTRzNiWnhQTVVENA?oc=5", "source_name": "Investing.com", "published_at": "2026-03-17T07:00:00+00:00", "published_display": "17 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantheus Holdings, Inc.'s (NASDAQ:LNTH) Stock Is Going Strong: Is the Market Following Fundamentals?", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxPZU9aUUEyY1gzaUViTmhQOUdjc3JjeWMzWFhyb1lWc0hOd0xFTGJXMUtQYmpEQi1ONEJmZVJGVm1mLTE1VHNRbEp5YTFWZWtqMW05d1IybWFGeDRzaFh6RUVna1lVZGJ5b19kcjRKS2hxRTRMWlpXUllteU9TcVNLczVJSjJkUQ?oc=5", "source_name": "Market source", "published_at": "2026-02-01T08:00:00+00:00", "published_display": "01 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Lantheus (LNTH) Stock Is Up Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxNd3lRVVJleHFMNE15aGV5STNtQWpfcEdiTXg5N0M1V1ZGS2Z0OWdoZWpXNkY0MGRUN3hQQ0hQZE5jYW8zVUplWThwc3NaVDc4Zi1JY2MzSjQwYVF3dlNPVXh2NkhsME1ETjRmTnFyRTdsQ0xMOWo2d3RMTGJIOXktXw?oc=5", "source_name": "Market source", "published_at": "2025-12-12T08:00:00+00:00", "published_display": "12 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LNTH Stock Price and Chart \u2014 NASDAQ:LNTH", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE1Bb19FbkRxbGFOck4tLVNwaTRrZjk4bVBkMjNpV0RteFZQZ2FBd193eTktcWVkd2U0blVqc1dGazhLcWFnVHVVYVEtMVBMY2dsVldzYms0SUNfektM?oc=5", "source_name": "TradingView", "published_at": "2025-07-28T07:00:00+00:00", "published_display": "28 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Lantheus Holdings (LNTH) Could Be 2% Undervalued Following Its Alzheimer Imaging Narrative", "summary": "Lantheus Holdings (LNTH) is gaining attention due to strong stock performance and its Alzheimer's disease imaging franchise, despite concerns about slowing revenue and margin pressures. The company's radiodiagnostic pipeline, including an FDA label expansion for Neuraceq and the ", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-lnth/lantheus-holdings/news/lantheus-holdings-lnth-could-be-2-undervalued-following-its/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-15T08:12:38", "published_display": "15 Jul 2026 08:12", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantheus Holdings, Inc. (LNTH) Stock Analysis: A 4.44% Potential Upside in the Healthcare Sector", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxQcVB2THhLQ0hmeDdsTmJYM1ZpR3I0YjF4UEJVMkhDWHkxZlVzVllBX2JtZlpGdEJNQ09kZEF0c3d1TWdyOXZadGN5VTl1R2RsWFpWQW44cVhkdGd4amtSRWJhQWwxMVMwT1g2NEhHYnZJQ2dQWG1sSlJSbDVxdjlKNENUV3ZOZW01N0QwQklEYm5FUjFzTGxjU3dkcUQzTGVodzRiclNpT3dGenZnaEJuSUphRGZfV3JTeG1yekkzSTFnZVRqV1hqR3o1NmVQd1dtVVhyQ29BWU0?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-13T09:22:36+00:00", "published_display": "13 Jul 2026 09:22", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantheus (LNTH) Q4 2024 earnings summary", "summary": "Lantheus (LNTH) reported record FY2024 revenue of $1.534 billion, an 18.3% year-over-year increase, primarily driven by strong sales of PYLARIFY and DEFINITY. PYLARIFY achieved blockbuster status with over $1 billion in annual sales, and DEFINITY also showed double-digit growth. ", "url": "https://quartr.com/events/lantheus-holdings-inc-lnth-q4-2024_oqQB0p8C", "source_name": "Quartr", "published_at": "2026-07-11T06:10:30", "published_display": "11 Jul 2026 06:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantheus (LNTH) M&A Announcement Summary", "summary": "Lantheus (LNTH) has announced an M&A deal designed to transform it into a fully integrated radiopharmaceutical leader by expanding manufacturing, broadening its pipeline, and entering new markets. The deal includes an upfront cash payment of $250 million plus up to $752.5 million", "url": "https://quartr.com/events/lantheus-holdings-inc-lnth-m-a-announcement_oqQB0xFg", "source_name": "Quartr", "published_at": "2026-07-11T02:41:14", "published_display": "11 Jul 2026 02:41", "sentiment": "positive", "sentiment_pct": 74, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantheus (LNTH) Q3 2025 earnings summary", "summary": "Lantheus reported Q3 2025 revenue of $384 million, a modest 1.4% year-over-year increase, with adjusted EPS at $1.27 and GAAP EPS significantly lower due to a 78.8% drop in net income. The company announced a leadership transition, completed key acquisitions of Life Molecular Ima", "url": "https://quartr.com/events/lantheus-holdings-inc-lnth-q3-2025_oqQB0zHN", "source_name": "Quartr", "published_at": "2026-07-11T02:41:14", "published_display": "11 Jul 2026 02:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "B. Riley Adjusts Price Target on Lantheus Holdings to $129 From $97, Maintains Buy Rating", "summary": "B. Riley has increased its price target for Lantheus Holdings (LNTH) to $129 from $97, while reiterating a Buy rating on the stock. This adjustment reflects a positive outlook on the company's financial prospects and market position.", "url": "https://www.moomoo.com/news/post/72719595/b-riley-adjusts-price-target-on-lantheus-holdings-to-129", "source_name": "Moomoo", "published_at": "2026-07-09T15:13:06", "published_display": "09 Jul 2026 15:13", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(LNTH) Movement as an Input in Quant Signal Sets", "summary": "This article provides a quantitative analysis of Lantheus Holdings Inc. (NASDAQ: LNTH), highlighting a weak near-term sentiment that could precede shifts in mid and long-term outlook. It identifies an exceptional 42.1:1 risk-reward short setup targeting a 12.0% downside against 0", "url": "https://news.stocktradersdaily.com/news_release/89/LNTH_Movement_as_an_Input_in_Quant_Signal_Sets_070826032201_1783538521.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-08T15:22:00", "published_display": "08 Jul 2026 15:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantheus Holdings Inc focuses on diagnostic imaging growth", "summary": "Lantheus Holdings Inc (LANT) specializes in advanced diagnostic imaging agents and therapeutic solutions, primarily for cardiovascular and oncology applications in the US market. The company's strategy focuses on innovation, rigorous clinical evidence, and navigating complex regu", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/lantheus-holdings-inc-focuses-on-diagnostic-imaging-growth/69716972", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T19:10:24", "published_display": "07 Jul 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantheus Holdings Inc (LNTH) Stock Down 6.4% but Still Overvalued -- GF Score: 82/100", "summary": "Lantheus Holdings Inc (LNTH) shares dropped 6.4% to $102.82 but are still considered overvalued according to GuruFocus's GF Value\u2122 which estimates its intrinsic value at $90.77. Despite a strong GF Score\u2122 of 82/100, indicating robust fundamentals in profitability and growth, its ", "url": "https://www.gurufocus.com/news/8946324/lantheus-holdings-inc-lnth-stock-down-64-but-still-overvalued-gf-score-82100", "source_name": "GuruFocus", "published_at": "2026-07-06T23:40:30", "published_display": "06 Jul 2026 23:40", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Did FDA\u2019s Facility-Related LNTH-2501 Delay and Russell Additions Just Reframe Lantheus Holdings\u2019 (LNTH) Risk Profile?", "summary": "Lantheus Holdings received a Complete Response Letter from the FDA for its LNTH-2501 PET imaging kit due to third-party manufacturing facility issues, not product safety or efficacy. Concurrently, the company was added to the Russell 2000 Defensive and Growth-Defensive Indexes, i", "url": "https://www.sahmcapital.com/news/content/did-fdas-facility-related-lnth-2501-delay-and-russell-additions-just-reframe-lantheus-holdings-lnth-risk-profile-2026-07-03", "source_name": "Sahm", "published_at": "2026-07-05T04:10:33", "published_display": "05 Jul 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LNTH - Lantheus Holdings Inc Latest SEC Filings", "summary": "This article provides the latest SEC filings information for Lantheus Holdings Inc. (LNTH), along with comprehensive financial data, performance metrics, and key ratios. It includes details on the company's market capitalization, income, sales, P/E ratio, insider ownership, insti", "url": "https://finviz.com/stock?t=LNTH&ta=1&p=d&ty=lf&b=2&page=20", "source_name": "Finviz", "published_at": "2026-07-04T16:39:52", "published_display": "04 Jul 2026 16:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantheus Holdings Inc focuses on diagnostic imaging and radiopharmaceutical growth", "summary": "Lantheus Holdings Inc is a specialized medical technology company that develops diagnostic imaging agents and radiopharmaceuticals for cardiology and oncology. The company's products help physicians visualize disease processes and improve diagnostic accuracy. Lantheus aims for lo", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/lantheus-holdings-inc-focuses-on-diagnostic-imaging-and/69680972", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-03T15:04:28", "published_display": "03 Jul 2026 15:04", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantheus Holdings stock hits 52-week high at 111.52 USD", "summary": "Lantheus Holdings stock reached a new 52-week high of $111.52, reflecting a strong 39.74% increase over the past year and investor confidence. This comes despite a recent FDA regulatory setback for its LNTH-2501 imaging kit due to manufacturing issues. Analysts like Citizens and ", "url": "https://www.investing.com/news/company-news/lantheus-holdings-stock-hits-52week-high-at-11152-usd-93CH-4768293", "source_name": "Investing.com", "published_at": "2026-06-30T16:10:08", "published_display": "30 Jun 2026 16:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantheus Holdings, Inc. (LNTH) Stock Analysis: Strong Buy Ratings Amid Impressive ROE and Expanding Diagnostic Portfolio", "summary": "Lantheus Holdings, Inc. (LNTH) is a strong player in the healthcare sector, particularly in diagnostic and therapeutic products, indicated by its $7.15 billion market cap and robust stock performance. The company exhibits impressive financial health with a 23.48% Return on Equity", "url": "https://www.directorstalkinterviews.com/lantheus-holdings-inc-lnth-stock-analysis-strong-buy-ratings-amid-impressive-roe-and-expanding-diagnostic-portfolio/4121255029", "source_name": "DirectorsTalk Interviews", "published_at": "2026-06-29T14:09:36", "published_display": "29 Jun 2026 14:09", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantheus Holdings (LNTH) New Product Narrative Keeps Valuation Questions In Focus", "summary": "Lantheus Holdings (LNTH) shares have recently seen significant movement, prompting investors to re-evaluate the company's valuation in light of its diagnostics and radiopharmaceutical portfolio. While market ratios suggest a balanced valuation, the company is considered modestly ", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-lnth/lantheus-holdings/news/lantheus-holdings-lnth-new-product-narrative-keeps-valuation", "source_name": "Simply Wall Street", "published_at": "2026-06-28T22:43:03", "published_display": "28 Jun 2026 22:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA issues complete response letter for Lantheus\u2019 NET imaging drug", "summary": "The FDA has issued a Complete Response Letter for Lantheus Holdings Inc.'s NET imaging drug, LNTH-2501, due to unresolved manufacturing issues at a third-party facility. The FDA's decision is not related to the drug's safety or efficacy data. Despite this setback, Lantheus shares", "url": "https://www.investing.com/news/company-news/fda-issues-complete-response-letter-for-lantheus-net-imaging-drug-93CH-4763391", "source_name": "Investing.com", "published_at": "2026-06-27T13:10:15", "published_display": "27 Jun 2026 13:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Lantheus Holdings, Inc. \u2013 NASDAQ:LNTH", "summary": "This page displays the enterprise value to revenue forward for Lantheus Holdings, Inc. (NASDAQ: LNTH). It provides financial data and historical values for this specific metric. The content appears to be a financial data point from TradingView related to the company's valuation.", "url": "https://www.tradingview.com/symbols/NASDAQ-LNTH/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T03:09:44", "published_display": "27 Jun 2026 03:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantheus stock falls after FDA rejects drug application By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxPRjlJSEE2RHZTQmlLZWgyUjdHQUMyNThkYzZ2U09Sbnd5WW9MRkVXQTVzbEROMDFleFdRN3R6TkdGMHA0Vm80bDBJTUtOYjFCd0ZlTnladVNlYlp6X1dibkdqMERiR29CY0FkaGRZX05EZnU2QWhhN3VHRlFyaG1FQjlPQUY3dHVQNGxfcHJyWDZyR1J4eV9fcmUxeXo2U2dMY0FidjE0THo2NGZNMmRkRkQ5X2pBZ1k?oc=5", "source_name": "Investing.com South Africa", "published_at": "2026-06-26T22:44:03+00:00", "published_display": "26 Jun 2026 22:44", "sentiment": "negative", "sentiment_pct": 22, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantheus Gets FDA Complete Response Letter for LNTH-2501", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/lantheus-gets-fda-complete-response-202202784.html", "source_name": "MT Newswires", "published_at": "2026-06-26T20:22:02+00:00", "published_display": "26 Jun 2026 20:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Lantheus Holdings, Inc. \u2013 NASDAQ:LNTH", "summary": "This page displays the forward Price to Sales ratio for Lantheus Holdings, Inc. (NASDAQ:LNTH). It appears to be a financial data point from TradingView, indicating a specific valuation metric for the company.", "url": "https://www.tradingview.com/symbols/NASDAQ-LNTH/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T21:10:58", "published_display": "26 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantheus stock falls after FDA rejects drug application", "summary": "Lantheus Holdings Inc. shares dropped after the FDA issued a Complete Response Letter for its LNTH-2501 drug application, citing unresolved manufacturing issues at a third-party facility. The FDA's decision was not related to the clinical safety or efficacy data of the drug, whic", "url": "https://www.investing.com/news/stock-market-news/lantheus-stock-falls-after-fda-rejects-drug-application-93CH-4763670", "source_name": "Investing.com", "published_at": "2026-06-26T21:10:58", "published_display": "26 Jun 2026 21:10", "sentiment": "negative", "sentiment_pct": 19, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US FDA declines Lantheus\u2019 tumor imaging kit over third-party manufacturing issues", "summary": "The U.S. FDA has declined to approve Lantheus Holdings' diagnostic imaging kit, LNTH-2501, for cancer tumors due to unresolved issues at a third-party manufacturing facility. This marks a setback for Lantheus, although the company stated that the FDA raised no concerns about the ", "url": "https://www.reuters.com/legal/litigation/us-fda-declines-approve-lantheus-tumor-imaging-kit-2026-06-26/", "source_name": "Reuters", "published_at": "2026-06-26T20:12:00", "published_display": "26 Jun 2026 20:12", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantheus Receives Complete Response Letter from FDA for LNTH-2501 (Ga 68 edotreotide)", "summary": "Lantheus announced that the FDA issued a Complete Response Letter for its New Drug Application for LNTH-2501, a diagnostic imaging agent for neuroendocrine tumors. The FDA's decision was due to unresolved manufacturing conditions at a third-party facility, not concerns about the ", "url": "https://www.manilatimes.net/2026/06/27/tmt-newswire/globenewswire/lantheus-receives-complete-response-letter-from-fda-for-lnth-2501-ga-68-edotreotide/2373966/amp", "source_name": "The Manila Times", "published_at": "2026-06-26T20:10:58", "published_display": "26 Jun 2026 20:10", "sentiment": "negative", "sentiment_pct": 10, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Lantheus Holdings Inc \u2013 XETR:0L8", "summary": "This article focuses on the \"Price to book forward\" metric for Lantheus Holdings Inc (XETR:0L8) as presented on TradingView. It appears to be a financial data snippet or a specific page from a financial tracking platform, indicating that the market for this stock is currently clo", "url": "https://www.tradingview.com/symbols/XETR-0L8/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T19:10:58", "published_display": "26 Jun 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantheus Holdings Inc Actuals & Estimates (NASDAQ:LNTH)", "summary": "This article provides an overview of Lantheus Holdings, Inc. (NASDAQ:LNTH) stock, including its current price, market capitalization, and historical performance. It also details analyst forecasts, financial actuals and estimates for earnings and revenue, and key financial metrics", "url": "https://www.tradingview.com/symbols/NASDAQ-LNTH/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T01:09:35", "published_display": "26 Jun 2026 01:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LNTH Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a detailed analyst forecast for Lantheus Holdings, Inc. (LNTH) stock for 2027, including a price target of 107.82 USD, with a max estimate of 117.00 USD and a min estimate of 94.00 USD. It covers various financial metrics such as price performance, market ca", "url": "https://www.tradingview.com/symbols/NASDAQ-LNTH/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T14:10:10", "published_display": "25 Jun 2026 14:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Beat And Cautious Outlook Could Be A Game Changer For Lantheus Holdings (LNTH)", "summary": "Lantheus Holdings (LNTH) recently surpassed Q1 analyst expectations for revenue and EPS due to strong demand for key products, while also reiterating its long-term plan. However, the company's full-year revenue guidance unexpectedly fell below analyst forecasts, indicating a caut", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-lnth/lantheus-holdings/news/earnings-beat-and-cautious-outlook-could-be-a-game-changer-f", "source_name": "Simply Wall Street", "published_at": "2026-06-25T04:40:23", "published_display": "25 Jun 2026 04:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Healthcare Equipment and Supplies Stocks Q1 Teardown: Lantheus (NASDAQ:LNTH) Vs The Rest", "summary": "This article analyzes the Q1 2026 earnings for healthcare equipment and supplies stocks, highlighting top performers like Lantheus (NASDAQ:LNTH) and STAAR Surgical (NASDAQ:STAA), and weaker performers such as Stryker (NYSE:SYK). It discusses industry trends, including innovation,", "url": "https://stockstory.org/us/stocks/nasdaq/lnth/news/earnings/healthcare-equipment-and-supplies-stocks-q1-teardown-lantheus-nasdaqlnth-vs-the-rest", "source_name": "StockStory", "published_at": "2026-06-24T09:10:24", "published_display": "24 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantheus Holdings stock hits 52-week high at 107.99 USD By Investing.com", "summary": "Lantheus Holdings Inc. (LNTH) stock reached a 52-week high of $107.99, demonstrating strong market performance with a significant year-to-date return of 59.58%. This achievement coincides with the company reporting strong Q1 2026 financial results, surpassing analyst expectations", "url": "https://ca.investing.com/news/stock-market-news/lantheus-holdings-stock-hits-52week-high-at-10799-usd-93CH-4703639", "source_name": "Investing.com", "published_at": "2026-06-23T15:09:25", "published_display": "23 Jun 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantheus: The Turnaround Is Working, But The Easy Money Has Been Made (NASDAQ:LNTH)", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxNQmdMZzB5WHh5UUo3aG9Zem54VEtid2tuV2RiWElya24tU3lXTXA5NGljVy10V0VFbHRoQklJTHlfa3VTMkxlRHhXUW1CSE05ajJoRGg3SzNoY3Y5R0hxQVhLMGZYSG0zM1Z2aTF3ZWE2dFIydWJnTlB1N0phcVBsMnRkcWVqZDM5RmJiNGxjZk54dUgwWXcwMDRCQmRfMi1XREJxZkN2MDNiRkwyR3hR?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-20T07:00:00+00:00", "published_display": "20 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantheus Holdings Inc (LNTH) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article provides an overview of the shareholder structure of Lantheus Holdings Inc (LNTH), detailing its major shareholders and institutional holdings. It lists the top institutional investors, including BlackRock, Janus Henderson Investors, and Farallon Capital Management, ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lnth/ownership", "source_name": "TradingKey", "published_at": "2026-06-19T18:10:29", "published_display": "19 Jun 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantheus (LNTH) Proxy filing Summary", "summary": "Lantheus (LNTH) recently filed a proxy statement detailing its upcoming annual meeting on April 30, 2026. Key items for shareholder vote include the election of four Class II directors, advisory votes on executive compensation, and a proposal to declassify the Board of Directors.", "url": "https://quartr.com/events/lantheus-lnth-proxy-filing_oqQBzjsc", "source_name": "Quartr", "published_at": "2026-06-19T14:10:29", "published_display": "19 Jun 2026 14:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantheus Holdings stock hits 52-week high at 104.05 USD", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxOTklNSXBHMkRPZXd5QnM3ZWh6cWdLMF83Q1JKeGVpa210NG1XYnFyUHptc2phWEtnY3J0WnRacUlGczg4T0ZRNGRsZFBzVS1jOVEzcFJxN29qVjNfeG4wenBUZy0yT1p1aUhTS3RNVkl0YkUzWmUxQ2RGRG9haExleEZuUVpwR0NrTUhvdjJQTWJKVkZXTUU2bUJKZ053Nm9nVUlvYWFkX01NLXhjbllR?oc=5", "source_name": "Investing.com", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Lantheus Holdings (LNTH) Valuation After Strong Multi Month Share Price Gains", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxOYkNrMm5kVFA5T2w0MkRzWlNTeW1SZzBleDE5RzJUQ0ZET2xmbERLVHk2MUk0OV9qMFpIeHJMb29zNGQzOEx5M0thUHFEaUx5V2pveGZKU2dCdXZiUHdlVFczT2xzVHk2dG9LVkdHTGpZaUVLRHVGbzhlQV9ZRFEtaVlyYkRfUE1JYThwczhHTkdQOHQ4V3NUUkZTQm9Nck81TTFnaU5EOHlXZWM?oc=5", "source_name": "Market source", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantheus (LNTH) CEO Heino reports 1,227-share tax withholding and updated holdings", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxOQlZObGdhdVU5VDlKYlpyY2JoQ1dfclRBNFZMVlgwdzhuUkJCUnhtVGJXbl9vYklmUTV5dXVSVXJRbHhBbkM3eTNHMXJweXo0c0ZqdVo1RVVDTi1BOTE5dkFFeU9TOEgwbGNMbmc0VWIwOUMxT3ZFMEE0blZCUnJnSnVpSEFBOTA2cXNzX3lndEJHNncxVFhJbEFaTlYycC1COW9iNFFmbkNkaDV6WnhMUzNOVVFXZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Radiopharma firm Lantheus to speak at Goldman Sachs health event", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxPM1FPNU1vVWp2OG5LQTE1OV9ybDMtVnpoTjVvQWpZUlMySlpmaWtHblNZeGlaMXRWUWYyc2NjVDdFVjBrTTJNa1oxWk5oQ25YeHZTOUo0MHNXS29YcEM2aHIzQjh5N2JBeTdiZ3FNT0t3b3RNMFdmcmthWnJBTWFBMzJMcmlaclg1dHBjWUwtZm5XemNENUR2a2Z6QmdmUEI0WDAtaHgyaUh6djlzUUVjRDBHTTc?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantheus ASCO Data To Test Radiopharma Pipeline And Valuation Gap Narrative", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Too Late To Consider Lantheus Holdings (LNTH) After Its Strong Share Price Run?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-24T07:00:00+00:00", "published_display": "24 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Story On Lantheus Holdings (LNTH) Is Shifting With PYLARIFY And Pipeline Expectations", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNckNrY1NXSHFyR3RQVWpWTEFDOTY1M1hfSFhoSkNzaGc1b055Z0k0c3poM29NaFpmaEJmYk9UcFBHS0IxRzFtM2RIb1ZzVFJLVkgzb1lsS3pOMXhUbDliN2VGaFVwcTl2ekd4N2lYc0V1bGhNQmJRcmpsLVZDZmdfX1FtT2wwNlhzYTNSYnpEckZzTVBPWm84MHlrVGJzT2VrQzk2ZA?oc=5", "source_name": "Market source", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantheus (LNTH) Considers Sale Following Curium Acquisition Prop", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxQbmQ5c0M0NnJDbElOem9YYy00Ym8xekItY3BINVFaSlA3dk1FOEhlZVhlcW85R0UyYS04WWFjeU4zOWt0VHB1MkdHQTZJUU5zV3I5Z3MtS294UVY1Yi1xRlhuVTJUVUtNRjhtTmtiREFWWW5GNXlTY1NGRGJnYzAzUWZhcS0ybElSN1dGTmJmeWlvLWEzZXVGTW9jbG5VdTBVRWVYbF9XWW1CSWF3SmpHT3kyV0xrcEFuZzBHV3V1VXd4ZmNFcERsYm14R0Ffdw?oc=5", "source_name": "GuruFocus", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantheus weighs potential $7 billion sale after Curium's offer, Bloomberg News reports", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQNkRQbmVpZUotZHFVdFNYaWpaOHZ6SkpId0xSSHd2NWtyNy1wZHJSa05pZ09OTlp1TGtZOHJReTdFUU9SOTBpeDN2dm51QVFFNVVYRlRaWHQtTnhSZVg4NzFyb0N2dk9mZXMzSUlDQy1STlJHd1JYMUwwNHprUjB5MlgwT0o0ZURzTEdua1dOQnA5cGQwUktsUXZQcExvSFhFWnJDaElKOTd5ZlNodFI1V1JGRWNUSVh0WXhF?oc=5", "source_name": "Reuters", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We Think You Should Be Aware Of Some Concerning Factors In Lantheus Holdings' (NASDAQ:LNTH) Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantheus Holdings (LNTH) Valuation Check After Q1 Earnings Beat And FDA Approval Catalysts", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxPUUtEaVdZdHhkSE8tZUc3VEZzN010MTVMeDI2eFRISS1NRmhaUmF2NjdRV2hKaWN4a1pyM0RhbGNWeUd6TFhEYXJlendTNXNWMGJNS09taVJXYlExa3NYR3A3Qk5pZ0pGWW93WUFVbXB2NEI2X3A3TWlyYlF1UXVjdEJjc1RXQzQzSWdtdVlJamRqWmtCRVlKallvVV91QWM0OUo3aGtR?oc=5", "source_name": "Market source", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here is Why Lantheus Holdings Inc (LNTH) Is Among the Best Medical AI Stocks to Invest In", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOZ3JuY2thSGRvQjJIclFnVVAySTRJNlBQV3NTT2ZtdFJjSm5RbEs1Wjh5Qk5kWnoyRjhlc0ltUDVKVGc2aEhVWDZxR2NoTUxrVUdEOVpJenRoaHdzeUpRNm9IZTZvdjA3UkZqbzdXaGpCbHBYMzBqdmxoakd4WU54X0Z5R3BlRjNmblVjdlAtMmNxaW1OQnNNOVpkRV91czBB?oc=5", "source_name": "Market source", "published_at": "2026-04-19T07:00:00+00:00", "published_display": "19 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantheus Says FDA Pushed Deadline For Reviewing Its Tumor Diagnostic Kit Application", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxNNkVRWHFkNDVuSno0ZDJVMzhpNF9oTm1WS2hBLVZ6ZkJBbDhZVEUyRm90NzdZbGVqeVV4aDJ3aWZEeWFFRDhJeTdMX3E3MjJJZVVnTG5KeUNmV2NLM3dlREd2YmpnWDI5TGpaS0gxOElYa1RzSEtBWVRBQnpyOW5VX2RTMERrZUtMQkFyMzVaX1JlMUZqSUtxZmx3bFNxa3lLR3lqcnVGU2tEbzgyaHdQaS1hSlFBTFB0LUVlSXJaNFlnY3pCeE5rckl2dE5admFSeGMwLW5qUjk1LWdm?oc=5", "source_name": "Stocktwits", "published_at": "2026-03-17T07:00:00+00:00", "published_display": "17 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA extends review of Lantheus\u2019 neuroendocrine tumor drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxNTzlnNG1WT0U3QlRrLXRZYmNpRTNXTW83TjB5Ml8xOThuSDhjam1kbUNiYWhkNG43RkNXRGNCc3V0ZWFib0dfSXE1UnhTVkZIWDVUT1FqWUtJdWJhSjRFT3h4RGh6UEczajdFZmJJV1E3MFJDbzZmczQtS1pCSHR5TnItbUpIVnBfbkN3cmNYdnBFNEpvUl84Nkpmei00bTd3TFVubllRNnVTRzNiWnhQTVVENA?oc=5", "source_name": "Investing.com", "published_at": "2026-03-17T07:00:00+00:00", "published_display": "17 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantheus Holdings, Inc.'s (NASDAQ:LNTH) Stock Is Going Strong: Is the Market Following Fundamentals?", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxPZU9aUUEyY1gzaUViTmhQOUdjc3JjeWMzWFhyb1lWc0hOd0xFTGJXMUtQYmpEQi1ONEJmZVJGVm1mLTE1VHNRbEp5YTFWZWtqMW05d1IybWFGeDRzaFh6RUVna1lVZGJ5b19kcjRKS2hxRTRMWlpXUllteU9TcVNLczVJSjJkUQ?oc=5", "source_name": "Market source", "published_at": "2026-02-01T08:00:00+00:00", "published_display": "01 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Lantheus (LNTH) Stock Is Up Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxNd3lRVVJleHFMNE15aGV5STNtQWpfcEdiTXg5N0M1V1ZGS2Z0OWdoZWpXNkY0MGRUN3hQQ0hQZE5jYW8zVUplWThwc3NaVDc4Zi1JY2MzSjQwYVF3dlNPVXh2NkhsME1ETjRmTnFyRTdsQ0xMOWo2d3RMTGJIOXktXw?oc=5", "source_name": "Market source", "published_at": "2025-12-12T08:00:00+00:00", "published_display": "12 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LNTH Stock Price and Chart \u2014 NASDAQ:LNTH", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE1Bb19FbkRxbGFOck4tLVNwaTRrZjk4bVBkMjNpV0RteFZQZ2FBd193eTktcWVkd2U0blVqc1dGazhLcWFnVHVVYVEtMVBMY2dsVldzYms0SUNfektM?oc=5", "source_name": "TradingView", "published_at": "2025-07-28T07:00:00+00:00", "published_display": "28 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 82, "total_relevant": 49, "sentiment_summary": {"positive": 13, "negative": 6, "neutral": 30, "score": 52, "total": 49, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 84, "events": [{"event": "general", "label": "Market update", "weight": 19.2, "count": 33}, {"event": "earnings", "label": "Earnings", "weight": 5.5, "count": 10}, {"event": "deals", "label": "Deals and strategy", "weight": 1.1, "count": 2}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}], "positive_events": 13, "negative_events": 6}, "market_context": {"has_market_context": true, "latest_close": 105.64, "latest_week": "2026-07-10", "one_week_move": -3.9, "four_week_move": 1.1, "twelve_week_move": 26.0, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.72724, "market_dynamics_buy_signal": false, "relative_strength": 26.878096, "fair_value_gap": 34.1, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 51.5878, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-3.9% over one week, +1.1% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 62, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Investing.com", "count": 6}, {"label": "TradingView", "count": 6}, {"label": "Market source", "count": 6}, {"label": "Quartr", "count": 4}, {"label": "Simply Wall Street", "count": 3}, {"label": "simplywall.st", "count": 3}, {"label": "DirectorsTalk Interviews", "count": 2}, {"label": "GuruFocus", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 49}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 33}, {"label": "Earnings", "count": 10}, {"label": "Deals and strategy", "count": 2}, {"label": "Analyst action", "count": 2}, {"label": "Guidance", "count": 1}, {"label": "Regulatory and legal", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "52/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "84/100 classification confidence."}, {"label": "Company focus", "value": "49", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "3", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-3.9% over one week, +1.1% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Lantheus Holdings (LNTH) Could Be 2% Undervalued Following Its Alzheimer Imaging Narrative"}], "updated_at": "2026-07-15T23:34:28.544389+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}